Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 12.8%

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 31,400 shares, a drop of 12.8% from the November 15th total of 36,000 shares. Based on an average daily trading volume, of 54,200 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC lifted its position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 392,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Armistice Capital LLC owned approximately 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission. 11.04% of the stock is currently owned by institutional investors.

Evaxion Biotech A/S Trading Down 8.9 %

Shares of NASDAQ:EVAX traded down $0.09 during midday trading on Tuesday, reaching $0.96. The company had a trading volume of 153,265 shares, compared to its average volume of 209,099. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a 1-year low of $0.91 and a 1-year high of $13.61. The firm has a market cap of $5.61 million, a price-to-earnings ratio of -3.24 and a beta of -0.39. The company has a fifty day simple moving average of $2.08 and a two-hundred day simple moving average of $2.70.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to analyst estimates of $0.19 million. Research analysts predict that Evaxion Biotech A/S will post -0.15 earnings per share for the current year.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.